RxDoctor Payments Data

Syed Alam, MD

Vascular Surgery · Battle Creek, MINPI 1619135480

Payments from drug & device makers

What this record shows

This record is dominated by other: $27,979 of the $37,184 with a category attached, or 75.2%. Angiodynamics, Inc. accounts for 76.9% of it on its own, with 37 other manufacturers making up the rest. Among vascular surgery clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,184in general payments, 2019–2025

Across 296 payments — averaging $125.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$29K
  • W. L. Gore & Associates, Inc.$2K
  • Endologix LLC$2K
  • Johnson & Johnson$820
  • Lemaitre Vascular, Inc.$517
  • Medtronic$489
  • plus $3K from 32 others

What the payments were for

  • Travel & lodging$8802%
  • Food & beverage$7,74021%
  • Education$5852%
  • Other$27,97975%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,184 in reported general payments places this provider in the 90th percentile of 183 vascular surgery providers in Michigan.

See all vascular surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$1,182,000
Medicare patients
339
Services billed
2,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban35$34,500
EliquisApixaban25$17,895
ClopidogrelClopidogrel Bisulfate196$3,036
Cephalexin29$436
Doxycycline Hyclate13$173
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$820$34,50035 claims
PfizerEliquis$176$17,89525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 183 vascular surgery providers in Michigan.

Other vascular surgery in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →